You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 62 No. 3, March 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Observation
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on ISI (3)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Neurology, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Carbon 13–Labeled Magnetic Resonance Spectroscopy Observation of Cerebral Glucose Metabolism

Metabolism in MELAS: Case Report

Taisuke Otsuki, MD, PhD; Tomoyuki Kanamatsu, PhD; Yasuzo Tsukada, MD, PhD; Yuichi Goto, MD, PhD; Kazuya Okamoto, BS; Hidehiro Watanabe, PhD

Arch Neurol. 2005;62:485-487.

Background  Carbon 13–labeled magnetic resonance spectroscopy (13C-MRS) with [1-13C]-glucose administration, the 13C atom that behaves as a radio inactive tracer in the brain, can differentiate aerobic and anaerobic glucose metabolism by detecting [4-13C]-glutamate (Glu C4) and [3-13C]-lactate (Lac C3).

Objective  To investigate the cerebral metabolic derangement resulting from mitochondrial dysfunction in mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS).

Design  Application of a new 13C-MRS technique to a patient with MELAS compared with control subjects (n = 7).

Patient  A 19-year-old woman with an A3243G mitochondrial mutation who underwent 13C-MRS for 30 minutes after oral administration of [1-13C]-glucose (0.75 g/kg).

Result  Decreased Glu C4–labeling (P<.001) and increased Lac C3 synthesis (>2 SDs) compared with controls were demonstrated in the patient with MELAS.

Conclusions  This first report on 13C-MRS observation of cerebral glucose metabolism in a patient with MELAS demonstrated the presence of low glutamate production via the tricarboxylic acid cycle compared with high lactate synthesis by glycolysis. The present findings suggest that the clinical use of 13C-MRS can be extended to diagnose mitochondrial dysfunction and monitor cerebral glucose metabolism in a variety of mitochondrial disorders.


Author Affiliations: Department of Neurosurgery, National Center Hospital for Mental, Nervous, and Muscular Disorders, National Center of Neurology and Psychiatry (Dr Otsuki), Institute of Life Science, Soka University (Drs Kanamatsu and Tsukada), and Mental Retardation and Birth Defect Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (Dr Goto), Tokyo, Japan; and Medical Systems Research and Development, Toshiba Corporation, Tochigi, Japan (Messers Okamoto and Dr Watanabe).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.